Dr. Baranzini’s current research involves large genomic studies in MS patients to characterize the overall risk and activity of genes during different stages of the disease, differential response to treatment, and disease progression. His research also involves immunological studies using the EAE model, sequencing of whole genomes and transcriptomes from patients with MS and developing bioinformatics tools to integrate this information with that coming from other high throughput technologies. In addition, Dr. Baranzini collaborates with several interdisciplinary teams worldwide to computationally integrate all the available knowledge obtained in different research domains. He also leads the iMSMS, an international consortium to study the effect of bacterial populations (microbiota) on MS susceptibility and progression. Dr. Baranzini earned his degrees in clinical biochemistry (1992) and PhD in human molecular genetics (1997) from the University of Buenos Aires, Argentina.
The Genomic Map Of Multiple Sclerosis: From Risk To Pathways
This talk will cover the latest research on MS genomics, including a large GWAS with more than 50,000 cases. It will also describe the next logical step in determining individual risk using cell-specific pathway analysis.